PepGen Inc. Faces Class Action Lawsuit over Misleading Securities Information Claims

PepGen Inc. Faces Legal Action for Securities Law Violations



In a significant development for shareholders of PepGen Inc. (NASDAQ: PEPG), a class action lawsuit has been filed against the company, raising serious allegations about its compliance with securities laws. The Gross Law Firm has announced that investors who purchased shares during the defined class period, from March 7, 2024, to March 3, 2025, should take note of the critical timeline and their rights concerning this lawsuit.

Background of the Allegations



The complaint against PepGen Inc. suggests that the company's management issued statements that were materially false or misleading. Specifically, it contends that:

1. Effectiveness of PGN-EDO51: The lead product candidate, PGN-EDO51, is claimed to be less effective and safe than previously represented to shareholders.
2. Dangerous CONNECT2 Study: The phase two CONNECT2 study is suggested to have significant deficiencies, jeopardizing its approval by the U.S. Food and Drug Administration (FDA).
3. Halt of Clinical Studies: The lawsuit implies that due to these issues, it is likely that PepGen will need to halt this critical clinical study, which could alter the commercial and regulatory prospects of PGN-EDO51.
4. Misleading Public Statements: The defendants' public statements were maintained to be materially deceptive throughout the relevant period, creating an artificially inflated stock value that did not reflect the company's actual standing.

Given the serious nature of these allegations, shareholders are urged not to delay in participating in this class action. By doing so, they may be eligible for recovery should the court find in favor of the plaintiffs.

How to Get Involved



Shareholders who acquired PEPG shares within the specified timeframe are encouraged to contact The Gross Law Firm. Registration for this class action is essential, and it allows investors to stay updated via portfolio monitoring tools created by the firm. The registration deadline is set for August 8, 2025. Notably, becoming a lead plaintiff is voluntary, and individuals are not required to undertake such a position to benefit from potential recovery efforts.

Investors can input their information through the official link provided by The Gross Law Firm, ensuring they do not miss out on their right to recover possible financial losses.

Next Steps and Legal Representation



The Gross Law Firm, recognized nationally for its dedication to protecting investor rights against corporate malfeasance, emphasizes that taking action is crucial for shareholders who feel misled. There are no charges for participating in this lawsuit, and the firm stresses that prior outcomes do not guarantee future results, yet their commitment to justice remains steadfast.

The firm's office is located at 15 West 38th Street, 12th floor, New York, NY, 10018, and they can be reached via email or their phone number for further inquiries. Investors are urged to act swiftly to secure their interests and bolster their claims against PepGen Inc.

Conclusion



This case will serve as an important litmus test for corporate accountability and shareholder rights in the biotech industry. As investors await further developments, the actions taken now could prove pivotal in determining the outcome of the allegations against PepGen Inc. Stakeholders are encouraged to stay vigilant and informed as this situation unfolds.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.